Eyes On Chugai's Hemlibra Supply Price As Sales Grow
Executive Summary
Set against what were seen as solid third quarter results, analysts are keeping an eye on planned changes to Chugai's supply price of Hemlibra to global licensee Roche.
Topics
- Subjects
- Commercial
- Business Strategies
- Manufacturing
- Therapy Areas
- Blood & Coagulation Disorders
- Regions
- Asia Pacific
- North America
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC124070
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC124070
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.